Drugs / VDV-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00740155 | Aug 2008 → Oct 2009 | Dengue hemorrhagic fever | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VDV-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00740155 ↗ |
| Modality | Vaccine | “VERO cell derived, live attenuated vaccine” PMID 25483647 ↗ 2014 |
| Route | Subcutaneous | “0.5 mL, Subcutaneous (SC)” NCT00740155 ↗ |